Genmab — Januar 2020

[JKY_VH]

og det gjorde vi, men hold da op for en rejse vi har været på i dag.

[Bulder]

Hvad har der været af corona-nyt som kan begrunde en sådan vending. Det er jo hele markedet.

[JKY_VH]

Ikke hvad jeg har hørt, men der er jo indkaldt til endnu et møde i
WHO-regi

[GeorgeBest]

følg med i Corona nyheder her (opdateres løbende) : https://www.cnbc.com/2020/01/30/coronavirus-latest-updates.html

[JKY_VH]

tak GB

[Bulder]

Det er nok frygt for, hvad WHO siger i aften.

[JKY_VH]

Ja og måske også Trump´s skæbne

[JKY_VH]

nok ikke i rigsretten men senere.

[E_L]

"Then there’s Novartis’ cancer drug Arzerra (ofatumumab), which the company has been working to repurpose in MS. Results from clinical trials of the drug have been so impressive that a group of physicians polled by SVB Leerink late last year listed it as one of the most promising choices for treating MS, even though it has not yet been approved for that use." https://www.fiercepharma.com/pharma/biogen-s-tecfidera-holds-its-own-ms-as-competitive-and-generic-threats-loom

[E_L]

Novartis: when you look at catalysts for 2020, another full year of catalysts, major approvals including the expected approval of ofatumumab, which we filed in December and used a priority review voucher.

[E_L]

that is how they still get it approved in H1

[E_L]

Novartis AG (NVS) CEO Vasant Narasimhan on Q4 2019 Results - Earnings Call Transcript - https://seekingalpha.com/article/4319978-novartis-ag-nvs-ceo-vasant-narasimhan-on-q4-2019-results-earnings-call-transcript?part=single

[E_L]

Ofatumumab, we are very, very excited about this opportunity, and we’re getting focus to bring this product as quickly as possible to patients. We filed both in the US and the EU. And I just want to spend a moment on this, because there is a real shift happening in the marketplace about how physicians treat MS. And this leads us to believe that we have a truly unique product profile with ofatumumab.

[E_L]

What physicians tell us is that they increasingly believe that it is best to use the most efficacious therapy upfront. And if you think about ofatumumab, we offer unsurpassed efficacy of B-cell depletion.

[E_L]

If you look at the chart on the left, which we presented at our R&D Day, you will see that the Confirmed Disability Worsening data is very impressive. If you combine that with a very favorable safety profile and easy mode of administration, we’ll have an autoinjector at launch, we were really proposing a winnings first line value proposition.

[E_L]

So our objective this year is to really focus on making sure that we can provide broad access to as many neurologists as possible, and of course, to as many patients as possible.

[E_L]

Q: First ofatumumab, could you remind us what are the resources that you will use to push the US launch in terms of sales force, and will you use medicine or Gilenya sales force as well or do you need to build new one ahead of the launch?

[E_L]

A: So on ofatumumab, obviously, we are resourcing to win and we’ve got a strong focus on the US also given the fact that we have submitted a PRV. We are looking to work with two separate sales forces. So one dedicated to ofatumumab and then of course, we have a sales force with Mayzent and Gilenya.

[E_L]

So we will be - we will be resourcing to win in this marketplace as I said to you before in the presentation, we firmly believe that we have a very unique value proposition with ofatumumab with unsurpassed efficacy and with B-cell depletion.

[E_L]

We’ve got an excellent safety profile, and also the ease-of-administration will - can really make this product a first-line choice for not only centers of excellence, but just the general neurologists.